Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg- -Naphthylamide-Inhibitable Efflux Pumps

V. Kothary, E. J. Scherl, B. Bosworth, Z.-D. Jiang, H. L. DuPont, J. Harel, K. W. Simpson, B. Dogan
  • Antimicrobial Agents and Chemotherapy, November 2012, ASM Journals
  • DOI: 10.1128/aac.02163-12

The authors haven't yet claimed this publication.

Read Publication


In partnership with: